Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Gilead is experiencing a significant year with the launch of Yeztugo and the completion of the Arcellx deal, indicating a strong focus on expanding its product portfolio [2] - The company reported an extraordinary performance in 2025, highlighted by major product launches and strong financial results, including disciplined operating expense control and significant growth in earnings per share (EPS) [3] Financial Performance - Gilead had two major product launches in 2025: Yeztugo and Livdelzi, which contributed to great financial performance [3] - The company is optimistic about its future, citing the strongest pipeline in its history and the beginning of a long cycle of product launches [3]